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Abstract
Background: Fragile × syndrome is caused by loss of expression of the FMRP protein involved in
the control of a large number of mRNA targets. The Drosophila ortholog dFXR interacts with a
protein complex that includes Argonaute2, an essential component of the RNA-induced silencing
complex (RISC). Furthermore dFXR associates with Dicer, another essential processing enzyme of
the RNAi pathway. Both microRNA and microRNA precursors can co-immunoprecipitate with
dFXR. Consequently it has been suggested that the Fragile × syndrome may be due to a defect in
an RNAi-related apparatus.
Findings: We have investigated the RNAi response in Fragile × patient cells lacking FMRP
compared with normal controls. RNAi responses were successfully detected, but no statistically
significant difference between the response in normal cells compared to patients cells was found -
neither one nor two days after transfection.
Conclusion: Our data show that in human fibroblasts from Fragile × patients lacking FMRP the
RNAi response is not significantly impaired.
Findings
Fragile × syndrome is caused by loss of expression of the
FMRP protein involved in the control of a large number of
mRNA targets [1]. The Drosophila ortholog dFXR inter-
acts with a protein complex that includes Argonaute2, an
essential component of the RNA-induced silencing com-
plex (RISC) [2]. Furthermore dFXR associates with Dicer,
another essential processing enzyme of the RNAi pathway
[3]. Both microRNA and microRNA precursors can co-
immunoprecipitate with dFXR [3], and it was shown that
FMRP can act as a miRNA acceptor protein for the ribonu-
clease Dicer and facilitate the assembly of miRNAs on spe-
cific target RNA sequences [4,5].
Consequently, it has been suggested that the Fragile × syn-
drome may be due to a defect in an RNAi-related appara-
tus [6] although in Drosophila S2 cells dFXR is not
required for an RNAi response [7]. RNAi is a naturally
occurring mechanism of gene regulation that induces
sequence-specific knock-down of gene expression at the
post-transcriptional level [8]. Regulation of gene expres-
sion by RNAi utilizes endogenous cellular pathways in
which double-stranded RNA molecules produced from
endogenous or foreign DNA are processed into short dou-
ble-stranded RNA molecules of 21-23 nucleotides. These
small interfering RNA (siRNA) molecules are incorpo-
rated into RISC that facilitates degradation of the target.
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embryo fibroblasts (MEFs) from FMRP wildtype or knock-
out (FMR1-/-) littermates [9]. Here it was shown that cells
lacking FMRP have normal RISC activity, since FMRP and
RISC were associated with distinct pools of mRNAs.
We have investigated the RNAi response in Fragile ×
patient cells lacking FMRP compared to fibroblasts from
normal individuals. Primary fibroblasts from patients and
controls were co-transfected with a luciferase plasmid and
siRNA oligonucleotides against the luciferase gene. As
control for the transfection frequency, cells were also
transfected with the plasmid lacZ encoding the beta-galac-
tosidase. As seen in Fig 1 RNAi responses were successfully
detected, but no statistically significant difference
between the response in normal cells compared to
patients cells was found - neither one nor two days after
transfection (two-tailed T-test). However, we cannot rule
out that the short term kinetics of the RNAi reponse in
normal and patient cells differ.
Conclusion
Our data support the conclusions made by Didiot et al.
that cells lacking FMRP have a normal RNAi response.
Since FMRP together with the autosomal paralogs FXR1P
and FXR2P constitutes a family of RNA bindings proteins,
it is conceivable that functional redundance exists among
these, contributing to the observed results [10]. Further
experiments are required to analyse the involvement of
FMRP in the miRNA pathway in human cells.
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Relative luciferase expression showing the RNAi response in human fibroblastsFigure 1
Relative luciferase expression showing the RNAi response in human fibroblasts. Primary human skin fibroblasts 
from two fragile × patients (Fra-X1 and 2) and a normal control person with a normal karyotype were transfected with the 
plasmid pGL3-basic (Promega) encoding luciferase and siRNA against the luciferase (GL3 siRNA, MWG-Biotech). GL3 siRNA 
targets the luciferase sequence 5'-CUUACGCUGAGUACUUCGATT -3' [11]. As control for the transfection frequency, cells 
were also transfected with the plasmid pCMVβ (Clontech) encoding beta-galactosidase. Luciferase and beta-galactosidase activ-
ities were measured one and two days after transfection using kits from Pierce and Promega, respectively. Transfections were 
performed in triplicates using X-tremeGeNE siRNA Transfection Reagent as suggested by the manufacturer (Roche). Subcon-
fluent cells in 25 cm2 tissue culture flasks were transfected with a mixture of 100 μl transfection reagent diluted in Opti-MEM 
together with 6 μg of each of the reporter plasmids and 2 μg of the siRNA oligonucleotides. The primary fibroblasts were 
obtained from 2 patients with a trinucleotide expansion leading to a full mutation in the FMR1 gene, and, thus, no FMRP pro-
tein detectable using western blotting (data not shown). A negative control siRNA with no significant homology to any known 
gene sequences from mouse, rat, or human was also purchased from MWG-Biotech. Shown on the Y-axes are the luciferase 
expression divided by the beta-galactosidase expression, setting the ratio to 100 for cells transfected without siRNA. Error 
bars: Standard deviation. The experiments comply with the National regulations on cells from approved biobanks. The primary 
human fibroblasts were cultured according to standard procedures and used in early passages.Page 2 of 3
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